ClinicalTrials.gg
RecruitingNCT06306170GYN-ARTUpdated Oct 22, 2026

Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)

An observational study in Gynecologic Cancer, Radiotherapy Side Effect and Radiotherapy; Complications, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Radiation Injuries with a site in Italy — 7 open to participants now, 8 under way, none of them phase 3. Radiation Injuries · Italy.

Planned enrollment
3rd of 10
1,000 · median 220
Started
2024
with 1 other
Observational
10 of 12
7 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
IRCCS San Raffaele

Among the 12 studies in Radiation Injuries with a site in Italy, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, and was the 8th registered.

Radiation Injuries

328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.

Browse Radiation Injuries studies →

Open to participants now

7 of the 12 studies in Radiation Injuries with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 76 Radiation Injuries studies recruiting now, 52 (68%) set no upper age limit and 14 (18%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Radiation Injuries with a site in Italy, or all of them as a file.
02

Study summary

This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed.

Read the detailed description

The patients with gynecological cancer treated with Advanced Radiotherapy (ART)- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- at the Department of Radiotherapy of "IRCCS San Raffaele Scientific Institute" (IRCCSSRaffaele) from January 2005 to January 2024 will be identified and their clinical and dosimetric data retrieved and analyzed.

The study objectives are the analysis of acute and late toxicity, and clinical outcomes, such as local, regional and distant control,disease free survival, cancer-specific survival, and overall survival. Secondary objective is the identification of prognostic factors for toxicity, disease progression, survival, including radiomic characteristics.

03

Conditions studied

  • Gynecologic Cancer
  • Radiotherapy Side Effect
  • Radiotherapy; Complications
  • Survivorship
  • Progression, Disease
  • Progression, Clinical

Keywords

  • Gynecologic Cancer
  • Image Guided Radiotherapy
  • PET/CT
  • Intensity Modulated Radiotherapy
  • Stereotactic Body Radiotherapy
  • Oligometastases
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Gynecologic cancer patients, > 18 years old, treated with IGRT, IMRT, SBRT

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • gynecologic cancer patients
  • >18 years old
  • treated with advanced radiotherapy techniques (IGRT, IMRT, SBRT)

Exclusion criteria

Exclusion Criteria:

  • other tumors
  • > 90 years old
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Gynecologic cancer patients

    Gynecologic cancer patients treated with IGRT, IMRT, SBRT (advanced radiotherapy-ART)

    Radiation: Image Guided Radiotherapy

Interventions

  • RadiationImage Guided Radiotherapy

    Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated

    Also known as: Intensity Modulated Radiotherapy, Stereotactic Body Radiotherapy

06

What researchers measure

Primary outcomes

  1. Local Relapse Free Survival

    local control (on the treated site) of the disease

    Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

  2. Regional Relapse Free Survival

    regional control (regional lymph nodal chain) of the disease

    Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

  3. Distant Metastases Free Survival

    distant metastases developed after the treatment

    Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

  4. Disease Free Survival

    absence of disease progression during the follow-up

    Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

  5. Overall Survival

    survival from all causes

    Time frame: From date of radiotherapy end until the date of death from any cause, assessed up to 120 months

  6. Cancer Specific Survival

    cancer survival

    Time frame: From date of radiotherapy end until the date of death from disease progression, assessed up to 120 months

Secondary outcomes

  1. Acute toxicity

    Toxicity developed in the first three months after the treatment, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity

    Time frame: Up to three months from the start of radiotherapy

  2. Late toxicity

    Toxicity developed after three months until the end of follow-up or death, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity

    Time frame: From three months after the start of radiotherapy until the end of follow-up or death, assessed up to 120 months

Other outcomes

  1. Predictive factors for disease progression and death

    Factors predicting survival. Survival trees, univariate/multivariate Cox regression models will be estimated to identify potential risk factors associated with survival outcomes

    Time frame: From radiotherapy end to date of local, regional progression, distant failure, or death, assessed up to 120 months

  2. Radiomic predictive factors for disease progression and death

    CT and PET/CT radiomic features predicting relapse or death will be extracted, acording to IBSI (Image Biomarker Standardisation Initiative), owning to the different families of features: Morphology, Statistical, Intensity Histogram, Grey Level Cooccurrence Matrix 3D-average, Grey Level Co-occurrence Matrix 3D-combined, Grey Level Run Lenght 3D-average. Grey Level Run Lenght 3D\_combined, Grey Level Size Zone Matrix 3D, Neighbors Grey Tone Difference Matrix 3D, Grey Level Distance Zone Matrix 3D, standard convolutional filters within radiomic workflow (wavelets, Laplacian of Gaussian)

    Time frame: From radiotherapy end to the first registered event (disease progression or death), assessed up to 120 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gavinski K, DiNardo D. Cervical Cancer Screening. Med Clin North Am. 2023 Mar;107(2):259-269. doi: 10.1016/j.mcna.2022.10.006. Epub 2022 Dec 26. PubMed 36759096 ↗
  • Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019 Apr;35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11. PubMed 30867104 ↗
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PubMed 35020204 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021 Dec 9;7(1):88. doi: 10.1038/s41572-021-00324-8. PubMed 34887451 ↗
  • Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023 Aug;162(2):383-394. doi: 10.1002/ijgo.14923. Epub 2023 Jun 20. PubMed 37337978 ↗
  • Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Mendez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PubMed 31908301 ↗
  • Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016 Jan;27(1):16-41. doi: 10.1093/annonc/mdv484. Epub 2015 Dec 2. PubMed 26634381 ↗
  • Tortorella L, Restaino S, Zannoni GF, Vizzielli G, Chiantera V, Cappuccio S, Gioe A, La Fera E, Dinoi G, Angelico G, Scambia G, Fanfani F. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021 Mar;32(2):e11. doi: 10.3802/jgo.2021.32.e11. Epub 2021 Jan 11. PubMed 33470061 ↗
  • Ramanathan S, Tirumani SH, Ojili V. Nodal metastasis in gynecologic malignancies: Update on imaging and management. Clin Imaging. 2020 Feb;59(2):157-166. doi: 10.1016/j.clinimag.2019.11.006. Epub 2019 Nov 28. PubMed 31821973 ↗
  • Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL; Gynecologic Oncology Group. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb;119(2 Pt 1):286-92. doi: 10.1097/AOG.0b013e318240de51. PubMed 22270280 ↗
  • Fournier M, Stoeckle E, Guyon F, Brouste V, Thomas L, MacGrogan G, Floquet A. Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients. Int J Gynecol Cancer. 2009 Nov;19(8):1307-13. doi: 10.1111/IGC.0b013e3181b8a07c. PubMed 20009882 ↗
  • Woelber L, Eulenburg C, Choschzick M, Kruell A, Petersen C, Gieseking F, Jaenicke F, Mahner S. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer. 2012 Mar;22(3):503-8. doi: 10.1097/IGC.0b013e31823eed4c. PubMed 22266935 ↗
  • Yang B, Zhu L, Cheng H, Li Q, Zhang Y, Zhao Y. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis. Radiat Oncol. 2012 Nov 23;7:197. doi: 10.1186/1748-717X-7-197. PubMed 23176540 ↗
  • Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, Powell MA, Grigsby PW. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1085-91. doi: 10.1016/j.ijrobp.2009.06.041. Epub 2009 Oct 31. PubMed 19880262 ↗
  • Chen CC, Lin JC, Jan JS, Ho SC, Wang L. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecol Oncol. 2011 Jul;122(1):9-13. doi: 10.1016/j.ygyno.2011.03.034. Epub 2011 Apr 22. PubMed 21514629 ↗
  • Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, Souhami L, Small W Jr, Berk L, Gaffney D. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e23-8. doi: 10.1016/j.ijrobp.2012.02.044. Epub 2012 Apr 28. PubMed 22543211 ↗
  • Jereczek-Fossa BA, Ronchi S, Orecchia R. Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):472-83. doi: 10.1016/j.rpor.2014.10.004. Epub 2014 Nov 7. PubMed 26696788 ↗
  • Ling DC, Vargo JA, Burton SA, Heron DE, Beriwal S. Salvage Curative-Intent Reirradiation Stereotactic Body Radiation Therapy for Isolated Pelvic and/or Paraortic Recurrences of Gynecologic Malignancies. Pract Radiat Oncol. 2019 Nov;9(6):418-425. doi: 10.1016/j.prro.2019.05.012. Epub 2019 May 28. PubMed 31150869 ↗
  • Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D'Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M, Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist. 2020 Feb;25(2):e311-e320. doi: 10.1634/theoncologist.2019-0309. Epub 2019 Oct 10. PubMed 32043791 ↗
  • Macchia G, Nardangeli A, Laliscia C, Fodor A, Draghini L, Gentile PC, D'Agostino GR, Balcet V, Bonome P, Ferioli M, Autorino R, Vicenzi L, Raguso A, Borghesi S, Ippolito E, Di Cataldo V, Cilla S, Perrucci E, Campitelli M, Gambacorta MA, Deodato F, Scambia G, Ferrandina G. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Int J Gynecol Cancer. 2022 Jun 6;32(6):732-739. doi: 10.1136/ijgc-2021-003237. PubMed 35193941 ↗
  • Macchia G, Pezzulla D, Campitelli M, Laliscia C, Fodor A, Bonome P, Draghini L, Ippolito E, De Sanctis V, Ferioli M, Titone F, Balcet V, Di Cataldo V, Russo D, Vicenzi L, Cossa S, Lucci S, Cilla S, Deodato F, Gambacorta MA, Scambia G, Morganti AG, Ferrandina G. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):321-332. doi: 10.1016/j.ijrobp.2023.04.025. Epub 2023 May 6. PubMed 37150261 ↗
  • Reshko LB, Baliga S, Crandley EF, Harry Lomas IV, Richardson MK, Spencer K, Bennion N, Mikdachi HE, Irvin W, Kersh CR. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. Gynecol Oncol. 2020 Dec;159(3):611-617. doi: 10.1016/j.ygyno.2020.10.001. Epub 2020 Oct 12. PubMed 33059914 ↗
  • Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):706-12. doi: 10.1016/j.ijrobp.2003.12.038. PubMed 15183474 ↗

Individual participant data

Plan to share: Yes — The data that support the findings of this study (anonymized individual participant data) are available on request from the corresponding author to researchers who provide a methodologically sound proposal. Requests made to the corresponding author (AF) will be evaluated by the Lombardy Territorial Ethics Committee

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: for another 2 years after the closure of the study

Access criteria: request from the corresponding author approved by the Lombardy Territorial Ethics Committee

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Mar 12, 2024
StartActual
Feb 15, 2024
Primary completionEst.
Feb 15, 2027
CompletionEst.
Feb 15, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 description edited
What changed in the outcomes
  • Descriptionother outcomeRadiomic predictive factors for disease progression and death: how it is measured was reworded
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionother outcomeRadiomic predictive factors for disease progression and death: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06306170
Lead sponsor
IRCCS San Raffaele
Responsible party
Andrei Fodor, MD (MD, IRCCS San Raffaele) — Principal investigator
First posted
Mar 12, 2024
Start date
Feb 15, 2024
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Andrei Fodor, MD
Contact
fodor.andrei@hsr.it
+390226437634
Nadia G Di Muzio, Prof
Contact
dimuzio.nadia@hsr.it
+390226437643
andrei Fodor, MD
principal investigator · IRCCS San Raffaele Scientific Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion